These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 2890458)

  • 1. The relationship between neuroleptic dosage and cognitive functioning in chronic schizophrenic patients.
    Hansen M; Paredes J; Koczapski A; Ledwidge B; Kogan C
    Clin Invest Med; 1987 Sep; 10(5):368-71. PubMed ID: 2890458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
    Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dosage piperacetazine (Quide) in ambulatory schizophrenic patients--therapeutic efficacy and toxicity.
    Donlon PT; Rada RT
    Dis Nerv Syst; 1974 May; 35(5):231-6. PubMed ID: 17894106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Second generation of neuroleptics--expectations and the reality].
    Jarema M
    Psychiatr Pol; 2002; 36(6 Suppl):209-16. PubMed ID: 12647441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
    Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living.
    Yoon JS; Kim JM; Lee H; Shin IS; Choi SK
    Hum Psychopharmacol; 2003 Dec; 18(8):627-33. PubMed ID: 14696022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.
    Goldberg TE; Weinberger DR
    J Clin Psychiatry; 1996; 57 Suppl 9():62-5. PubMed ID: 8823353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Patient modified medication: how do schizophrenic patients manage their neuroleptics?].
    Hornung WP; Buchkremer G; Redbrake M; Klingberg S
    Nervenarzt; 1993 Jul; 64(7):434-9. PubMed ID: 8103569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
    Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
    Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schizophrenic thinking and neuroleptic dosage.
    Puente AE; Andersson C
    J Clin Psychol; 1987 Mar; 43(2):189-97. PubMed ID: 2883201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Premorbid IQ and schizophrenia. Increasing cognitive reduction by episodes.
    Eberhard J; Riley F; Levander S
    Eur Arch Psychiatry Clin Neurosci; 2003 Apr; 253(2):84-8. PubMed ID: 12799746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tricyclic antidepressants dosage and depressed elderly inpatients: a retrospective pharmaco-epidemiologic study].
    Ballon N; Siobud-Dorocant E; Even C; Slama F; Dardennes R
    Encephale; 2001; 27(4):373-6. PubMed ID: 11686060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with reduction in antipsychotic medication dosage in adults with mental retardation.
    Luchins DJ; Dojka DM; Hanrahan P
    Am J Ment Retard; 1993 Jul; 98(1):165-72. PubMed ID: 8103998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.